[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gi-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gi-cancers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718",false,"NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device","ALL","18 Years",{"count":18,"type":19},180,"ESTIMATED","INTERVENTIONAL",[22],"NA","Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[25,26,27,28,29,30,31],"Cancer","Breast Cancer","Prostate Cancer","Colon Cancer","GI Cancers","Ovarian Cancer","Pancreatic Cancer",[33,34,35,36,37,25,38,39,40],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model","RECRUITING","2026-06-19",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-04-30",{"date":49,"type":19},"2027-03",{"name":51,"class":52},"Unity Health Toronto","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100637149","the-canopy-cancer-collective-clinical-registry-protocol-100637149","NCT07605702","The Canopy Cancer Collective Clinical Registry Protocol","Inclusion Criteria:\n\nRetrospective Cohort:\n\n1. Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama\u002FNebraska 19; Puerto Rico 21).\n2. Must have histologically proven GI cancer seen at the site within the 20 years preceding activation, and are:\n\n   1. Deceased, or\n   2. Lost to follow-up ( \\>1 year lapse in contact since last visit).\n\nProspective Cohort:\n\n1. Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama\u002FNebraska 19; Puerto Rico 21).\n2. Must have histologically proven Gastrointestinal (GI) cancer.\n3. Patient or legally authorized representative capable of understanding and willing to provide signed informed consent (assent if applicable).\n4. Patient\u002FLegally Authorized Representative (LAR) agrees to collection of clinical data and information available on archival tissue and subsequent excess specimens obtained as part of standard-of-care.\n\nExclusion Criteria:\n\nRetrospective Cohort:\n\n1\\. Cases in which patient's medical chart denotes restricted use of health information.\n\nProspective Cohort:\n\n1\\. Prisoners will not be approached for participation.",{"count":61,"type":19},100000,"2 Years","OBSERVATIONAL","The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol\n\nNumber of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes.\n\nSecondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory.\n\n2\\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory.\n\nResearch Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes.\n\nDrugs\u002FDevices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and\u002For their affiliates Sample Size Up to 30000 patients in the prospective component\n\nUp to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival",[66,31,67,29,68,69,70],"Gastrointestinal Neoplasms","Colorectal Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","PDAC","GI Cancer","NOT_YET_RECRUITING","2026-05-18",{"date":74,"type":45},"2026-05-26",{"date":76,"type":19},"2026-05",{"date":78,"type":19},"2038-05",{"name":80,"class":81},"Canopy Cancer Collective, LLC","NETWORK",10,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":20,"phases":92,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100609590","phase-1-first-in-human-study-of-7mw4911-in-gi-cancer-100609590","NCT07216560","First-in-human Study of 7MW4911 in GI Cancer","A Phase I\u002FII Study of 7MW4911 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Advanced Colorectal Cancer and Other Advanced Gastrointestinal Tumors","Inclusion Criteria:\n\n1. Aged 18 and above\n2. ECOG 0-1\n3. Life expectancy ≥ 3 months\n4. Advanced or metastatic gastrointestinal cancer that has progressed after standard of care.\n5. Disease progression after the most recent treatment regimen\n6. At least one measurable lesion according to RECIST v1.1\n7. Provision of archival tumor tissue or fresh biopsy.\n8. Adequte hematologic funciton, liver function and renal function.\n9. Comply with contraceptive requirements\n\nExclusion Criteria:\n\n1. Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.\n2. Active, untreated or symptomatic CNS metastasis\n3. Effusions that require frequent drainage\n4. Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.\n5. Severe respiratory disease that required hospitalization in the last 28 days.\n6. Significant and uncontrolled cardiovascular disease or events in the 6 months prior to study drug administration\n7. Poorly controlled blood glucose with fasting blood glucose above 10mmol\u002FL\n8. Recipient of allogeneic stem cell transplant or organ transplant\n9. Active HIV or hepatitis B\u002FC infection. Infection requiring systemic IV in the 14 days prior to study drug administration.\n10. Experiencing toxicities from prior anti-cancer therapies that have not recovered to CTCAE grade 0-1, except for alopecia and endocrinopathies.\n11. Prohibited treatment and treatment that requires washout period\n\n    1. Has received another Topo-I payload ADC, and\u002For another CDH17 targeting therapy.\n    2. Received other cancer therapy within 5 half-lives or 21 days prior to study drug administration.\n    3. Major surgeries within 28 days prior to study drug administration\n    4. Investigational therapy within 28 days prior to study drug administration\n    5. Systemic treatment with immunosuppressive agents within 28 days prior to first drug administration. Physiological dose of glucocorticoid, topical glucocorticoid are allowed.\n    6. Use of strong CYP3A4 inhibitor or inducer\n12. Known hypersensitivity to 7MW4911 or components of the formulation\n13. Abuse of narcotic or psychoactive drugs\n14. Pregnant or breastfeeding women\n15. Other circumstances or conditions where the investigator judges to be unsuitable for study.",{"count":91,"type":19},200,[93,94],"PHASE1","PHASE2","This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.",[29],"2026-04-29",{"date":47,"type":45},{"date":100,"type":45},"2026-01-13",{"date":102,"type":19},"2028-12",{"name":104,"class":105},"Mabwell (Shanghai) Bioscience Co., Ltd.","INDUSTRY",5]